✦ LIBER ✦

38 POSTER Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors

✍ Scribed by F.A.L.M. Eskens; M.J.A. de Jonge; L. van Doorn; T. Isoe; K. Hayashi; S. Hussain; L. Ekman; H. Burger; J. Verweij

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of lon

✍ Carlos Castaneda; Kellen L. Meadows; Roxanne Truax; Michael A. Morse; Scott H. K 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 358 KB

A Phase I, open-label, dose escalation s

✍ John Marshall,Jimmy Hwang,Ferry A. L. M. Eskens… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 223 KB

A phase I dose escalation study of BIBW

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

137 A phase I study of an oral vascular

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

72 POSTER Phase I, safety, pharmacokinet

✍ H. Gelderblom; J. Verweij; N. Steeghs; E. de Koning; A. van Erkel; L. van Doorn; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

396 A Phase I, Dose-finding Study of BI

✍ de Jonge, M.; Sahebjam, S.; Mathijssen, R.H.; Razak, A.; van der Biessen, D.; Pr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB